307 related articles for article (PubMed ID: 12839948)
1. Oncolytic vesicular stomatitis virus for treatment of orthotopic hepatocellular carcinoma in immune-competent rats.
Ebert O; Shinozaki K; Huang TG; Savontaus MJ; García-Sastre A; Woo SL
Cancer Res; 2003 Jul; 63(13):3605-11. PubMed ID: 12839948
[TBL] [Abstract][Full Text] [Related]
2. Eradication of advanced hepatocellular carcinoma in rats via repeated hepatic arterial infusions of recombinant VSV.
Shinozaki K; Ebert O; Woo SL
Hepatology; 2005 Jan; 41(1):196-203. PubMed ID: 15619242
[TBL] [Abstract][Full Text] [Related]
3. A Novel Chimeric Oncolytic Virus Vector for Improved Safety and Efficacy as a Platform for the Treatment of Hepatocellular Carcinoma.
Abdullahi S; Jäkel M; Behrend SJ; Steiger K; Topping G; Krabbe T; Colombo A; Sandig V; Schiergens TS; Thasler WE; Werner J; Lichtenthaler SF; Schmid RM; Ebert O; Altomonte J
J Virol; 2018 Dec; 92(23):. PubMed ID: 30232179
[TBL] [Abstract][Full Text] [Related]
4. Oncolysis of hepatic metastasis of colorectal cancer by recombinant vesicular stomatitis virus in immune-competent mice.
Huang TG; Ebert O; Shinozaki K; García-Sastre A; Woo SL
Mol Ther; 2003 Sep; 8(3):434-40. PubMed ID: 12946316
[TBL] [Abstract][Full Text] [Related]
5. Oncolysis of multifocal hepatocellular carcinoma in the rat liver by hepatic artery infusion of vesicular stomatitis virus.
Shinozaki K; Ebert O; Kournioti C; Tai YS; Woo SL
Mol Ther; 2004 Mar; 9(3):368-76. PubMed ID: 15006603
[TBL] [Abstract][Full Text] [Related]
6. Prophylactic alpha interferon treatment increases the therapeutic index of oncolytic vesicular stomatitis virus virotherapy for advanced hepatocellular carcinoma in immune-competent rats.
Shinozaki K; Ebert O; Suriawinata A; Thung SN; Woo SL
J Virol; 2005 Nov; 79(21):13705-13. PubMed ID: 16227290
[TBL] [Abstract][Full Text] [Related]
7. Enhanced oncolytic activity of vesicular stomatitis virus encoding SV5-F protein against prostate cancer.
Chang G; Xu S; Watanabe M; Jayakar HR; Whitt MA; Gingrich JR
J Urol; 2010 Apr; 183(4):1611-8. PubMed ID: 20172545
[TBL] [Abstract][Full Text] [Related]
8. Systemic therapy of experimental breast cancer metastases by mutant vesicular stomatitis virus in immune-competent mice.
Ebert O; Harbaran S; Shinozaki K; Woo SL
Cancer Gene Ther; 2005 Apr; 12(4):350-8. PubMed ID: 15565179
[TBL] [Abstract][Full Text] [Related]
9. Combined VSV oncolytic virus and chemotherapy for squamous cell carcinoma.
Sung CK; Choi B; Wanna G; Genden EM; Woo SL; Shin EJ
Laryngoscope; 2008 Feb; 118(2):237-42. PubMed ID: 18043494
[TBL] [Abstract][Full Text] [Related]
10. The oncolytic effect of recombinant vesicular stomatitis virus is enhanced by expression of the fusion cytosine deaminase/uracil phosphoribosyltransferase suicide gene.
Porosnicu M; Mian A; Barber GN
Cancer Res; 2003 Dec; 63(23):8366-76. PubMed ID: 14678998
[TBL] [Abstract][Full Text] [Related]
11. Oncolytic vesicular stomatitis viruses are potent agents for intravesical treatment of high-risk bladder cancer.
Hadaschik BA; Zhang K; So AI; Fazli L; Jia W; Bell JC; Gleave ME; Rennie PS
Cancer Res; 2008 Jun; 68(12):4506-10. PubMed ID: 18559493
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-12 expression enhances vesicular stomatitis virus oncolytic therapy in murine squamous cell carcinoma.
Shin EJ; Wanna GB; Choi B; Aguila D; Ebert O; Genden EM; Woo SL
Laryngoscope; 2007 Feb; 117(2):210-4. PubMed ID: 17204993
[TBL] [Abstract][Full Text] [Related]
13. Oncolytic vesicular stomatitis virus administered by isolated limb perfusion suppresses osteosarcoma growth.
Kubo T; Shimose S; Matsuo T; Fujimori J; Sakaguchi T; Yamaki M; Shinozaki K; Woo SL; Ochi M
J Orthop Res; 2011 May; 29(5):795-800. PubMed ID: 21437961
[TBL] [Abstract][Full Text] [Related]
14. Exponential enhancement of oncolytic vesicular stomatitis virus potency by vector-mediated suppression of inflammatory responses in vivo.
Altomonte J; Wu L; Chen L; Meseck M; Ebert O; García-Sastre A; Fallon J; Woo SL
Mol Ther; 2008 Jan; 16(1):146-53. PubMed ID: 18071337
[TBL] [Abstract][Full Text] [Related]
15. Oncolytic recombinant herpes simplex virus for treatment of orthotopic liver tumors in nude mice.
Chung YS; Miyatake S; Miyamoto A; Miyamoto Y; Dohi T; Tanigawa N
Int J Oncol; 2006 Apr; 28(4):793-8. PubMed ID: 16525626
[TBL] [Abstract][Full Text] [Related]
16. Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma.
Blechacz B; Splinter PL; Greiner S; Myers R; Peng KW; Federspiel MJ; Russell SJ; LaRusso NF
Hepatology; 2006 Dec; 44(6):1465-77. PubMed ID: 17133484
[TBL] [Abstract][Full Text] [Related]
17. Sensitivity of prostate tumors to wild type and M protein mutant vesicular stomatitis viruses.
Ahmed M; Cramer SD; Lyles DS
Virology; 2004 Dec; 330(1):34-49. PubMed ID: 15527832
[TBL] [Abstract][Full Text] [Related]
18. VSV-G pseudotyped, MuLV-based, semi-replication-competent retrovirus for cancer treatment.
Qiao J; Moreno J; Sanchez-Perez L; Kottke T; Thompson J; Caruso M; Diaz RM; Vile R
Gene Ther; 2006 Oct; 13(20):1457-70. PubMed ID: 16724095
[TBL] [Abstract][Full Text] [Related]
19. Target gene therapy for alpha-fetoprotein-producing hepatocellular carcinoma by E1B55k-attenuated adenovirus.
Ohashi M; Kanai F; Tateishi K; Taniguchi H; Marignani PA; Yoshida Y; Shiratori Y; Hamada H; Omata M
Biochem Biophys Res Commun; 2001 Mar; 282(2):529-35. PubMed ID: 11401492
[TBL] [Abstract][Full Text] [Related]
20. Enhanced oncolytic potency of vesicular stomatitis virus through vector-mediated inhibition of NK and NKT cells.
Altomonte J; Wu L; Meseck M; Chen L; Ebert O; Garcia-Sastre A; Fallon J; Mandeli J; Woo SL
Cancer Gene Ther; 2009 Mar; 16(3):266-78. PubMed ID: 18846115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]